Neurogene Inc. (NGNE) Stock Profile — Insider Trades & Financials

Revenue$0

Net Income-$24.7M

EPS$-3.11

Market Cap$335.7M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Rachel McMinn

CEO & Executive Director

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.

Founded: 2003
Employees: 131
Headquarters: New York, New York, United States

⚡

Core Efficiency

ROE?

-9.34%

ROA?

-8.57%

D/E Ratio?

0.09

📊

Profitability Ratios

Current Ratio?

16.56

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Sep 3, 2026 (in 147 days)

Annual Report (10-K) — Based on filing pattern

Sep 3, 2026

Predicted10-K

Mar 24, 2026

10-KQ4 20256d after period end

Mar 24, 2026

10-KFY 202583d after period end

Nov 13, 2025

10-QQ3 20252d after period end

Aug 11, 2025

10-QQ2 20255d after period end

May 9, 2025

10-QQ1 20254d after period end

Mar 24, 2025

10-KQ4 20246d after period end

Mar 24, 2025

10-KFY 202583d after period end

Nov 18, 2024

10-QQ3 20245d after period end

Loading company sections...

Neurogene Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness